News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,411 Results
Type
Article (14947)
Company Profile (299)
Press Release (267159)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80083)
Career Advice (171)
Deals (13361)
Drug Delivery (40)
Drug Development (50735)
Employer Resources (33)
FDA (5853)
Job Trends (5188)
News (145412)
Policy (10091)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (924)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21821)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6048)
Artificial intelligence (260)
Autoimmune disease (110)
Automation (9)
Bankruptcy (108)
Best Places to Work (4577)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3128)
Cardiovascular disease (237)
Career advice (157)
Career pathing (8)
CAR-T (218)
CDC (5)
Cell therapy (564)
Cervical cancer (14)
Clinical research (43700)
Collaboration (1149)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1101)
CRISPR (86)
C-suite (552)
Cystic fibrosis (112)
Data (4316)
Decentralized trials (1)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1379)
Digital health (10)
Diversity (6)
Diversity, equity & inclusion (10)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31671)
Editorial (25)
Employer branding (4)
Employer resources (32)
Events (51729)
Executive appointments (622)
FDA (7601)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (981)
Gene editing (182)
Generative AI (22)
Gene therapy (486)
GLP-1 (504)
Government (1152)
Grass and pollen (3)
Guidances (166)
Healthcare (6629)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (23)
IPO (7349)
IRA (12)
Job creations (871)
Job search strategy (135)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (11)
Legal (1404)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (25)
Management (8)
Manufacturing (376)
MASH (130)
Medical device (2672)
Medtech (2681)
Mergers & acquisitions (6632)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2052)
Non-profit (876)
Now hiring (30)
Obesity (329)
Opinion (126)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26784)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15474)
Phase 2 (20299)
Phase 3 (12835)
Pipeline (3240)
Policy (91)
Postmarket research (859)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1455)
Recruiting (14)
Regulatory (9901)
Reports (19)
Research institute (975)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2008)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (26)
Worklife (2)
Date
Last 7 days (345)
Last 30 days (1157)
Last 365 days (17803)
2026 (1653)
2025 (18104)
2024 (20557)
2023 (22428)
2022 (26906)
2021 (27923)
2020 (23473)
2019 (16300)
2018 (11809)
2017 (13774)
2016 (11860)
2015 (14367)
2014 (10420)
2013 (7499)
2012 (7575)
2011 (7644)
2010 (7446)
Location
Africa (158)
Alabama (66)
Alaska (2)
Arizona (72)
Arkansas (5)
Asia (18271)
Australia (3115)
California (7076)
Canada (1838)
China (775)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39216)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (37)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5580)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (827)
North Dakota (6)
Northern California (3474)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (218)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (904)
United States (23330)
Utah (96)
Virginia (137)
Washington D.C. (38)
Washington State (592)
West Virginia (1)
Wisconsin (45)
282,411 Results for "accent therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Accent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical Study
January 29, 2026
·
1 min read
Press Releases
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
January 13, 2026
·
3 min read
Press Releases
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
October 9, 2025
·
2 min read
Press Releases
Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2025
·
5 min read
Press Releases
Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting
May 23, 2025
·
4 min read
Genetown
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting
Accent Therapeutics presents advances in cancer targeting at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
April 8, 2024
·
6 min read
Press Releases
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
March 25, 2025
·
5 min read
Press Releases
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
April 28, 2025
·
6 min read
Genetown
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing.
January 23, 2024
·
5 min read
Genetown
Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced four upcoming presentations and posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
March 21, 2024
·
4 min read
1 of 28,242
Next
